The roadmap to geographic atrophy treatment: A journey of trials and promise-Reference-Cited by-同舟云学术

The roadmap to geographic atrophy treatment: A journey of trials and promise

Published:2023-11-07 Issue:8 Volume:101 Page:891-895
ISSN:1755-375X
Container-title:Acta Ophthalmologica
language:en
Short-container-title:Acta Ophthalmologica

Author:

Trivizki Omer¹²^ORCID,Loewenstein Anat²,Zur Dinah²^ORCID

Affiliation:

1. Department of Ophthalmology, Bascom Palmer Eye Institute University of Miami, Miller School of Medicine Miami Florida USA

2. Ophthalmology Division, Tel Aviv Medical Center, Faculty of Medicine Tel Aviv University Tel Aviv Israel

Abstract

AbstractThis review covers advancements in geographic atrophy (GA) research. It discusses genetic contributions to AMD, explores treatment strategies, including complement inhibition, and highlights recent FDA approvals, safety concerns and promising future directions.

Publisher

Wiley

Subject

Ophthalmology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/aos.15801

Reference22 articles.

1. Phase I/IIa clinical trial of human embryonic stem cell (hESC)‐derived retinal pigmented epithelium (RPE, OpRegen) transplantation in advanced dry form age‐related macular degeneration (AMD): interim results;Banin E.;Investigative Ophthalmology & Visual Science,2019

2. Alternative Complement Pathway Inhibition by Lampalizumab

3. The Role of the Complement Pathway in Clinical Progression of Geographic Atrophy

4. Complement, age‐related macular degeneration and a vision of the future. Archives of ophthalmology;Gehrs K.M.;Chicago, Ill. 1960,2010

5. Efficacy of intravitreal pegcetacoplan in patients with geographic atrophy (GA): 12‐month results from the phase 3 OAKS and DERBY studies;Goldberg R.;Investigative Ophthalmology & Visual Science,2022